Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoOx quantum dots

Five years of advances in electrochemical analysis of protein biomarkers in lung cancer: a systematic review

Lung cancer is the leading cause of cancer death in both men and women. It represents a public health problem that must be addressed through the early detection of specific biomarkers and effective treatment. To address this critical issue, it is imperative to implement effective methodologies for specific biomarker detection of lung cancer in real clinical samples. Electrochemical methods, including microfluidic devices and biosensors, can obtain robust results that reduce time, cost, and assay complexity. This comprehensive review will explore specific studies, methodologies, and detection limits and contribute to the depth of the discussion, making it a valuable resource for researchers and clinicians interested in lung cancer diagnosis.

A fluorescence immunoassay based on GSH destroying MnO2@QDs for the simultaneous ultrasensitive detection of four mycotoxins in cereals

A novel fluorescence immunoassay based on MnO₂ nanoflowers loading multicolor quantum dots and glutathione destroying MnO₂ nanoflowers to release quantum dots combined with magnetic separation is developed for rapid, ultra-sensitive, and simultaneous quantitative detection of ochratoxin A, aflatoxin B₁, fumonisin B₁, and zearalenone in cereal samples. The test linear range of assay is from 0.001 to 200 μg L^-1. The limit of detection for ochratoxin A, aflatoxin B₁, fumonisin B₁, and zearalenone is 0.0001 μg L^-1, 0.0001 μg L^-1, 0.0003 μg L^-1, and 0.0001 μg L^-1, respectively. The simultaneous detection of four mycotoxins can be achieve within 30 min. The test results of four mycotoxins in the incurred corn, rice, and oat samples have been confirmed by ultra-performance liquid chromatography tandem mass spectrometry, the differences between results are considered no significantly different (p > 0.05). This multiplexed test scheme has provided a potential analysis strategy for multiple food risk factors.

Photoelectrochemical sandwich immunoassay of CYFRA21-1 based on In2O3/WO3 type-II heterojunction and CdS quantum dots-polydopamine nanospheres labeling

Using an In₂O₃/WO₃ type-II heterojunction modified fluorine-doped tin oxide (FTO) electrode as the photoanode and CdS quantum dots (QDs)-polydopamine nanospheres (PDA NSs) as the secondary antibody (Ab₂) label, the photoelectrochemistry (PEC) sandwich immunosensing of the lung cancer marker CYFRA21-1 was studied. WO₃ nanoplates were prepared by a hydrothermal method, In₂O₃ nanoporous spheres were prepared by a hydrothermal method followed by calcination, and the In₂O₃/WO₃ type-II heterojunction with high PEC activity was prepared by ultrasonic mixing and cast-coating. PDA NSs with a high surface area can be loaded with abundant Ab₂ molecules and many CdS QDs with an energy level well matched with the heterojunction, so the photocurrent signal can be amplified by the formation of a sandwich immunostructure. Through the simulation experiments of photoelectrode-modified chitosan films of varying thickness, the effective transport distance of photogenerated charges is preliminarily discussed. Under the optimized conditions, the photocurrent was linear with the common logarithm of CYFRA21-1 concentration from 100 fg mL^-1 to 50 ng mL^-1, with a limit of detection of 56 fg mL^-1 (S/N = 3). The immunoassay of CYFRA21-1 in human serum samples gave satisfactory recovery results.

Applications and Immunological Effects of Quantum Dots on Respiratory System

Quantum dots (QDs), are one kind of nanoscale semiconductor crystals with specific electronic and optical properties, offering near-infrared mission and chemically active surfaces. Increasing interest for QDs exists in developing theranostics platforms for bioapplications such as imaging, drug delivery and therapy. Here we summarized QDs’ biomedical applications, toxicity, and immunological effects on the respiratory system. Bioapplications of QDs in lung include biomedical imaging, drug delivery, bio-sensing or diagnosis and therapy. Generically, toxic effects of nanoparticles are related to the generation of oxidative stresses with subsequent DNA damage and decreased lung cells viability in vitro and in vivo because of release of toxic metal ions or the features of QDs like its surface charge. Lastly, pulmonary immunological effects of QDs mainly include proinflammatory cytokines release and recruiting innate leukocytes or adaptive T cells.

An ultrasensitive ratiometric immunosensor based on the ratios of conjugated distyrylbenzene derivative nanosheets with AIECL properties and electrochemical signal for CYFRA21-1 detection

Aggregation-induced electrochemiluminescence reagent, a distyrylbenzene derivative with donor-acceptor conjugated nanosheet structure, namely TPAPCN, was used as a trace label and modified on the electrode through the formation of classical sandwich complex of antibody-antigen-antibody in this work. In aggregate state, TPAPCN with twisted structure was limited in nanometer space through intermolecular π - π stacking interactions, which not only restricts the intramolecular motions but also combines a large number of singlet excitons to greatly trigger electrochemiluminescence (ECL). The ECL signal of this system enhanced with more captured cytokeratin 19 fragment 21-1 (CYFRA21-1) on the modified electrode. Three-dimensional graphene/platinum nanoparticles with large specific surface, and excellent electroconductivity and biocompatibility were prepared and acted as excellent carriers for thionine handling (3D-GN/PtNPs/Th), which was employed for improving the loading of antibodies and generating internal electrochemical signal. Consequently, a novel ratiometric sandwich immunosensor for CYFRA21-1 detection was fabricated based on TPAPCN and 3D-GN/PtNPs/Th, that is, a rapid and reliable detection was achieved through the ratio between ECL and electrochemical signals. The prepared sensor performed good linearity in the range of 50 fg/mL to 1 ng/mL with a detection limit as low as 16 fg/mL. Moreover, the detection results revealed well in the analysis of human serum samples, demonstrating a significant application for clinical monitoring and biomolecules detection.

Electrochemiluminescent immunoassay for the determination of CA15-3 and CA72-4 using graphene oxide nanocomposite modified with CdSe quantum dots and Ru(bpy)3 complex

A novel immunoassay is introduced based on co-reactant enhancing strategy for the electrochemiluminescent (ECL) determination of CA15-3 and CA72-4 tumor markers in real samples. For the preparation of the signaling probe, CA15-3 and CA72-4 antibodies first were labeled using Ru(bpy)₃²⁺-N-hydroxysuccinimide ester (Ru(bpy)₃²⁺-NHS) and conjugated with L-cysteine capped cadmium selenide (CdSe) quantum dots. Finally, it was cross-linked with chitosan-grafted graphene oxide (GO@CS) nanocomposite. The capture probe was constructed by deposition of multi-walled carbon nanotubes (MWCNT) at the surface of dual-working gold screen-printed electrodes (MWCNT-dwSPE) and covalent attachment of capture CA15-3 and CA72-4 antibodies to MWCNT-dwSPE. ECL signals were recorded by applying cyclic potential ranging from 0.3 to 1.1 V (vs. pseudo-reference Ag/AgCl) at the scan rate of 100 mV.s^-1. This immunoassay was used for determination of CA15-3 and CA72-4 in real samples the detection limits of 9.2 μU.ml^-1 and 89 μU.ml^-1 within linear ranges of 10 μU.ml^-1-500 U.ml^-1 and 100 μU.ml^-1-150 U.ml^-1, respectively. This immunoassay also showed acceptable accuracy with recoveries in the range 96.5-108 % and high reproducibility with RSD of 3.1 and 4.9.

Recent Advancements in Nanoparticle-Based Optical Biosensors for Circulating Cancer Biomarkers

The effectiveness of cancer treatment strongly depends on the early detection of the disease. Currently, the most common diagnostic method, tissue biopsy, takes time and can be damaging to the patient. Circulating cancer biomarkers such as circulating tumor DNA, micro-RNA (miRNA), tumor proteins, exosomes, and circulating tumor cells have repeatedly demonstrated their viability as targets for minimally invasive cancer detection through liquid biopsies. However, among other things, achieving a great sensitivity of detection is still challenging due to the very low concentration of biomarkers in fluid samples. This review will discuss how the recent advances in nanoparticle-based biosensors are overcoming these practical difficulties. This report will be focusing mainly on optical transduction mechanisms of metal nanoparticles (M-NPs), quantum dots (QDs), and upconversion nanoparticles (UCNPs).

Electrochemical ultrasensitive detection of CYFRA21-1 using Ti3C2Tx-MXene as enhancer and covalent organic frameworks as labels

The concentration level of cytokeratin fragment antigen 21-1 (CYFRA21-1) can be used as an important indicator for predicting non-small cell lung cancer (NSCLC). Here, a sandwich-type electrochemical immunosensor for ultrasensitive detection of CYFRA21-1 is developed. The sensor based on a combination of gold nanoparticle (AuNPs) decorated Ti₃C₂T_x-MXene (Au-Ti₃C₂T_x) as the substrate enhancer, and toluidine blue (TB) modified AuNPs doped covalent organic framework (COF) polymer as the signal tag (TB-Au-COF). The Au-Ti₃C₂T_x is used to capture numerous primary antibodies and accelerate the electron transfer rate of the substrate, while the TB-Au-COF can be applied to provide a large number of signal units TB and secondary antibodies. These features of composites endow the proposed immunosensor with high sensitivity and current response to CYFRA21-1. Under optimum conditions, the immunosensor offers a wide current response for CYFRA21-1 from 0.5-1.0 × 10⁴ pg·mL^-1 with a detection limit of 0.1 pg·mL^-1. Furthermore, the biosensing platform can be applied for CYFRA21-1 detection to analyze real serum samples, providing an effective and useful avenue for the applicability of Au-Ti₃C₂T_x and TB-Au-COF composite materials in biosensing field.

Recent Progress of Lung Cancer Diagnosis Using Nanomaterials

Lung cancer is one of the serious malignant tumors with high morbidity and mortality due to the poor diagnosis and early metastasis. The developing nanotechnology provides novel concepts and research strategies for the lung cancer diagnosis by employing nanomaterials as diagnostic reagents to enhance diagnostic efficiency. This commentary introduces recent progress using nanoparticles for lung cancer diagnosis from two aspects of in vivo and in vitro detection. The challenges and future research perspectives are proposed at the end of the paper.

Recent developments in electrochemiluminescence nanosensors for cancer diagnosis applications

In recent years, electrochemiluminescence (ECL) nanosensing systems have undergone rapid development and made significant progress in ultrasensitive analysis and cell imaging. Because of the unique advantages of high selectivity, ultra-sensitivity, and good reproducibility, ECL nanosensors can open new paths for cancer diagnosis. With the development of ECL nanosensors, high-throughput analysis, visual detection and spatially resolved ECL imaging of single cells are being realized. The innovations of ECL nanosensors consist of electrochemical excitation, coreactant catalysis, light radiation and luminescence signal amplification, which involve several fields such as nanotechnology, catalysis, optics, and electrochemistry. The developments of ECL instruments also relate to imaging technology. Herein, we review the construction modes, sensing strategies and cancer diagnosis applications of ECL nanosenors. Firstly, the nano-components of the ECL sensing system are discussed. The construction and signal amplification methods of the nanosensing system are emphasized. Secondly, the high-efficiency cancer identification strategies are presented, including protein tumor marker detection, nucleic acid assay, cancer cell identification and exosome detection. The recent advances in representative examples of ECL nanosenors in cancer diagnosis are highlighted, including high-throughput ECL analysis, in situ assay, visual ECL detection, single-cell imaging diagnosis, and so on. Finally, the challenges are featured based on the recent development of the ECL nanosensing system in the clinical diagnosis. The ECL nanosensors provide effective and reliable analytical methods and open new paths for cancer diagnosis. It is noteworthy that the prospects of the ECL nanosensing system in clinical diagnosis are instructive to the developments of other nanosensor research.